At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 810 enrolled
Drug / intervention
Insulin Glargine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride
In Brief
A Phase 3 clinical trial evaluating Insulin Glargine, LY2189265, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 810 participants across 78 sites in 20 countries.
Detailed Summary
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes. Participants must also be taking metformin and glimepiride.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesArgentina, Australia, Belgium, Brazil, Canada, Croatia, Czechia, France, Greece, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, South Korea, Spain, Sweden, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedFeb 2010
Primary CompletionMay 2012
Study CompletionNov 2012
TodayJul 2026
First PostedFeb 25, 2010
Enrollment StartFeb 1, 2010
Primary CompletionMay 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.4 years ago
Interventions
Insulin Glarginedrug
LY2189265drug
Metformindrug
Glimepiridedrug